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Inhibitory coupling of receptors to adenylate cyclase previously has been shown to be
relatively sensitive to inactivation by alkylation with N-ethylmaleimide (NEM).
Modification of the inhibitory guanine nucleotide regulatory protein, N1, has been
proposed to be responsible for this effect. The effects of NEM on GTP-sensitive
binding of carbachol to muscarinic cholinergic receptors has been compared in a cell
line (1321Ni human astrocytoma cells) in which these receptors stimulate
phosphoinositide breakdown and in a cell line (NG108-15 neuroblastoma x glioma
cells) in which activation of these receptors results in inhibition of adenylate cyclase.
Pretreatment of membrane preparations from 1321 NI cells with NEM resulted in a
concentration-dependent decrease in the extent of pertussis toxin-catalysed
[32P]ADP-ribosylation of a 41 OOODa protein previously proposed to be the a subunit
of N j. Under conditions where 32P-labelling of Ni in 1321 N I membranes was reduced
by NEM by 90%, no effect was observed on the extent ofguanine nucleotide-sensitive
high-affinity binding of carbachol to muscarinic cholinergic receptors. In contrast,
treatment of NG 108-15 membranes with NEM under the same conditions resulted in
complete loss of high-affinity guanine nucleotide sensitive binding of carbachol.
These results illustrate another difference between the muscarinic receptor
population of these two cell lines, and support the previous proposal that muscarinic
receptors of 1321N I cells couple to a guanine nucleotide regulatory protein that is not
Ni.
Activation of muscarinic cholinergic receptors
of 1321N1 human astrocytoma cells results in
attenuation of cyclic AMP accumulation (Meeker
& Harden, 1982; Harden et al., 1985). Although a
functional inhibitory guanine nucleotide binding
protein, Ni, is present, muscarinic receptors
apparently do not couple to N, to inhibit adenylate
cyclase in these cells (Hughes et al., 1984). Rather,
attenuation of cyclic AMP accumulation occurs as
a result of activation of a calcium-dependent cyclic
nucleotide phosphodiesterase (Meeker & Harden,
1982; Harden et al., 1985).
Abbreviations used: NEM, N-ethylmaleimide; Ni, the
guanine nucleotide regulatory protein that couples
receptors to inhibition of adenylate cyclase; GTPyS,
guanosine 5'-[8-thioltriphosphate; QNB, quinuclidinyl
benzilate.
* To whom correspondence and reprint requests
should be addressed.
Agonist occupancy of muscarinic receptors of
1321N 1 cells also has been shown to result in an
increase in phosphoinositide breakdown and uni-
directional Ca2+ efflux (Masters et al., 1984). We
have recently reported that the affinity of muscar-
inic receptors of 1321 N 1 cells for carbachol
is modulated by guanine nucleotides (Evans
et al., 1985). However, pertussis toxin, which
ADP-ribosylates and functionally inactivates Ni
(Katada & Ui, 1982; Bokoch et al., 1984), has no
effect on GTP-sensitive high-affinity binding of
cholinergic agonists in membranes from these
cells. This and other evidence led us to suggest that
a guanine nucleotide regulatory protein that is not
Ni may be involved in coupling the muscarinic
receptor of 1321 NI cells to the effector system
responsible for breakdown of phosphoinositides,
mobilization of Ca2+, and activation of protein
kinase C and cyclic nucleotide phosphodiesterase
(Evans et al., 1985; Harden et al., 1985).
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In the present paper we present additional
evidence to support this hypothesis. Treatment of
membranes with NEM previously has been
demonstrated to inactivate Ni. Thus, guanine
nucleotide modulation of the affinity of inhibitory
receptors for agonists (Wei & Sulakhe, 1980;
Harden etal., 1982; Kilpatrick et al., 1982; Korn et
al., 1983; Yeung & Green, 1983; Smith & Harden,
1984) and receptor- or guanine nucleotide-medi-
ated inhibition of adenylate cyclase (Jakobs et al.,
1982; Harden et al., 1982; Smith & Harden, 1984)
are abolished following treatment with relatively
low concentrations of NEM. Here we confirm a
direct effect of NEM on Ni by showing a
concentration-dependent blockage of pertussis
toxin-catalysed [32PIADP-ribosylation of a 41 kDa
substrate thought to be the a subunit of Ni (Ui,
1984; Bokoch et al., 1984). In contrast to this effect
of NEM on N, and on GTP-sensitive high-affinity
binding of carbachol in membranes from a cell line
(NG 108-15 neuroblastoma x glioma cells) that ex-
presses an adenylate cyclase-linked muscarinic
receptor, NEM has no effect on guanine nucleotide
modulation of agonist affinity for muscarinic
receptors of 1321 N I cells.
Materials and methods
Materials
Dulbecco's modified Eagle medium, trypsin and
fetal calf serum were purchased from Gibco.
Carbamylcholine chloride (carbachol), atropine,
NEM, Hepes, EDTA and dithiothreitol were
obtained from Sigma, and GTPyS was from
Boehringer Mannheim. [3H]QNB (33.1 Ci/mmol)
was from New England Nuclear. [32P]ATP syn-
thesized by the method of Walseth & Johnson
(1979) was used to synthesize [32P]NAD as
described (Cassel & Pfeuffer, 1978).
Cell culture and pertussis toxin treatments
1321NI human astrocytoma cells and NG 108-
15 neuroblastoma x glioma cells were grown for 4-
7 days as previously described (Evans et al., 1984).
Pertussis toxin was partially purified from Borde-
tella pertussis (strain 165) as previously described
(Hughes et al., 1984). 1321 NI cells were treated
for 16h with 1 pg of toxin/ml in the presence
of streptomycin (50pg/ml) and penicillin (50
units/ml).
Preparation of membranes
1321 N 1 astrocytoma cell membranes were pre-
pared by aspirating the medium, washing the cell
surface with lOmM-Hepes buffer (pH7.5 at 4°C),
and swelling the cells in lOml of lOmM-Hepes
buffer. After 15min on ice, the cells were scraped
from the dish with a rubber policeman and the
suspension was centrifuged at 40000g for 1Omin at
4°C. The resulting pellet was resuspended in
lOmM-Hepes/l0mM-EDTA (pH 7.5 at 4°C) with a
Brinkmann Polytron (setting 6.0 for 15 s) and the
suspension was centrifuged as before. This wash-
ing procedure was repeated twice more. Mem-
branes not used immediately were stored at - 80°C
in 50mM-Hepes (pH 7.5) containing 250 mM-su-
crose and 5mM-MgCl2. For experiments involving
pertussis toxin-catalysed ADP-ribosylation, mem-
branes were purified by sucrose gradient centrifu-
gation as previously described (Hughes et al.,
1984). Preparation of membranes from NG 108-15
cells was as previously described (Evans et al.,
1984).
Assay of muscarinic cholinergic receptors
Competition binding experiments were con-
ducted essentially as previously described (Evans
et al., 1984, 1985) in a final volume of 10ml in
polypropylene tubes containing membrane pro-
tein, [3H]QNB (20-35pM), carbachol and GTPyS
where indicated in l0mM-Hepes buffer (pH7.5 at
37°C) containing 5 mM-MgCl2. Incubations were
for 90min at 37°C. Nonspecific binding was
defined as the amount of [3H]QNB bound in the
presence of l /IM-atropine. All assays were per-
formed in triplicate.
NEM treatment
Washed membranes from 1321N1 or NG108-15
cells were resuspended in lOmM-Hepes (pH7.5 at
40C)/lOmM-EDTA/150mM-NaCl and the indi-
cated concentration of NEM. After a 30min
incubation on ice, an equimolar concentration of
dithiothreitol was added and the membranes were
pelleted by centrifugation at 40000g for 20min at
4°C. The membrane pellets then were resuspended
in lOmM-Hepes/5mM-MgCI2 for binding assays.
ADP-ribosylation by pertussis toxin
Control membranes or membranes pretreated
with NEM were incubated with pertussis toxin
and [32P]NAD for 90min at 30°C as described in
detail elsewhere (Hughes et al., 1984; Evans et al.,
1985). Following the ribosylation reaction the
membranes were washed repeatedly, solubilized,
and subjected to electrophoresis on 12.5% poly-
acrylamide slab gels (Laemmli, 1970). The gels
were stained, destained, dried, and autoradio-
grams exposed for 1-3 days. The extent of
incorporation of [32P]ADP-ribose into the 41 kDa
subunit of Ni was assessed by densitometric
analysis of autoradiograms with a Kontes model




Muscarinic receptors of 1321N 1 astrocytoma cells
Results
Pretreatment of membranes with NEM pre-
viously has been demonstrated to abolish effects of
guanine nucleotides on agonist binding to muscar-
inic cholinergic (Wei & Sulakhe, 1980; Harden et
al., 1982; Korn et al., 1983; Smith & Harden,
1984), a2-adrenergic (Jakobs et al., 1982), adeno-
sine (Yeung & Green, 1983), dopamine (Kilpatrick
et al., 1982) and opiate (Larsen et al., 1981; Smith
& Harden, 1984) receptors and inhibitory coupling
of these receptors to adenylate cyclase (Jakobs et
al., 1982; Harden et al., 1982; Smith & Harden,
1984). N, is apparently much more susceptible to
inactivation by NEM than is the stimulatory
guanine nucleotide binding protein, N, (Harden et
al., 1982). Further indication of the sensitivity of
Ni to NEM is presented in Fig. 1. As has been
previously reported (Hughes et al., 1984), incuba-
tion of 1321N1 membranes with [32P]NAD and
pertussis toxin results in incorporation of 32p into a
41 kDa substrate (Fig. 1). The work of Ui and
coworkers (Katada & Ui, 1982; Murayama & Ui,
1983; Ui, 1984) and Gilman and coworkers
(Bokoch et al., 1983, 1984) has confirmed that this
protein is the a subunit of Ni. Labelling of the
41 kDa substrate was prevented by pretreatment of
whole cells with pertussis toxin (lane 4, Fig. 1). In
addition, the extent of incorporation of [32P]ADP-
ribose into the 41 kDa substrate was reduced by
pretreatment of membranes with NEM; 32p-
labelling was inhibited by 80(90% with 1OMM-
NEM (lane 3, Fig. 1). A concentration-effect curve




Fig. 1. Autoradiogram of sodium dodecyl sulphate/poly-
acrylamide gel oJ pertussis toxin-labelled 1321N1 cell
plasma membrane proteins
Membranes were pretreated with NEM, [32P]ADP-
ribosylated, solubilized, and labelled proteins were
resolved by electrophoresis and autoradiography as
described in the Materials and methods section.
Lane 1, control membranes; lane 2, membranes
treated with I mM-NEM; lane 3, membranes treated
with lOQM-NEM; lane 4, membranes from cells
pretreated overnight with pertussis toxin (1 jg/ml).
45K and 31 K indicate the mobility of 45 and 31 kDa
protein standards.
concentration of NEM required for half-maximal
blockade of 32P incorporation was 3gM (n = 3).
We recently have reported that GTP and its
analogs markedly reduce the apparent affinity of
muscarinic receptors of 1321N 1 astrocytoma cells
for the agonist carbachol (Evans et al., 1985). This
effect of guanine nucleotides on receptor affinity
for agonists is characteristic of receptor systems
that couple to guanine nucleotide regulatory
proteins (Rodbell, 1980; Limbird, 1981). The fact
that pretreatment of 1321 NI membranes with
pertussis toxin has no effect on guanine nucleotide-
sensitive binding of carbachol to muscarinic
receptors (Evans et al., 1985) suggests that N, does
not mediate the guanine nucleotide effect on
receptor affinity. In contrast, the guanine nucleo-
tide-mediated reduction in muscarinic receptor
affinity for agonists in NG108-15 cells has been
shown to be blocked by pertussis toxin (Kurose et
al., 1983; Evans et al., 1984). Since pretreatment of
membranes with NEM directly modifies the
guanine nucleotide binding subunit of Ni (Figs. 1
and 2), it was of interest to determine if this
covalent modification was capable of inhibiting







Fig. 2. Blockade oJ pertussis toxin-catalysed [32P]ADP-
ribosylation of Ni by NEM pretreatment
Purified 1321 N 1 membranes were treated with the
indicated concentrations of NEM and then incu-
bated with pertussis toxin and [32P]NAD as
described in the Materials and methods section.
Following solubilization and sodium dodecyl
sulphate/polyacrylamide-gel electrophoresis, an
autoradiogram of the dried gel was developed. The
Figure shows the relative density of the labelled
band migrating at a position corresponding to
41 kDa. Each point represents the mean+ S.D. for





binding of carbachol to muscarinic receptors of
1321N1 cells. As shown in Fig. 3, pretreatment of
1321N1 cell membranes with l0OMm-NEM had no
effect on the competition binding curve for
carbachol carried out either in the absence or
presence of GTPyS. In contrast, NG108-15 cell
membranes treated with lOOpM-NEM under the
same conditions displayed lower apparent affinity
for carbachol than untreated membranes, and
GTPyS failed to modify further the competition
curve (Fig. 4). Thus, as we have previously
demonstrated (Smith & Harden, 1984), coupling of
muscarinic receptors of NG 108-15 cells to N, is
very sensitive to inactivation by NEM.
Although pretreatment of 1321N I membranes
with lOyM-NEM reduced pertussis toxin-catalysed
[32P]ADP-ribosylation of N, by 80%, concentra-
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Fig. 3. Efject oJ NEM on agonist binding to muscarinic
receptors of 1321NI cells
Carbachol competition curves in the presence (a)
and absence (@) of IO iM-GTPyS were generated as
described in the Materials and methods section
using control (upper panel) and NEM (100pM)-
pretreated (lower panel) 1321N1 cell membranes.
Specific binding is shown on the ordinate as the
percentage of the total specific binding measured in
the absence of carbachol. Each point represents the
mean of triplicate assays. The data are representa-
tive of results from three experiments.
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significant effect on [3H]QNB binding alone
(results not shown), or on the capacity of 10/uM-
carbachol to inhibit [3H]QNB binding either in the
absence or presence of GTPyS (Fig. 5). Thus, in
contrast to the marked sensitivity to NEM of
pertussis toxin-catalysed ADP-ribosylation of Ni
in 1321 N 1 cell membranes and GTP-sensitive
cholinergic agonist binding (Fig. 4) and N,-
mediated inhibition of adenylate cyclase (Smith &
Harden, 1984) in NG108-15 cells, GTP-sensitive
binding of carbachol to muscarinic receptors of
1321 NI cells is insensitive to very high concentra-
tions of this alkylating agent.
Discussion
Recent evidence has led us to propose (Evans et
al., 1985; Harden et al., 1985) that even though a
common biochemical event, attenuation of cyclic
AMP accumulation, is observed following stimula-
tion of muscarinic receptors on 1321 N 1 astrocy-
toma and NG 108-15 neuroblastoma x glioma cells,
this end response may be: (1) initiated by different
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Fig. 4. Effect of NEM on agonist binding to muscarinic
receptors of NG108-15 cells
Carbachol competition curves in the presence (0)
and absence (0) of lOpM-GTPyS were generated as
described in the Materials and methods section for
control (upper panel) and NEM (10O0M)-pretreated
(lower panel) NG108-15 cell membranes. The data
are representative of results from six experiments.
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Fig. 5. Concentration-dependence ofthe ejfect ofNEM on
the affinity of carbachol in 1321N1 membranes
Washed membranes were treated with the indicated
concentrations of NEM, washed, and then assayed
for [3H]QNB binding in the absence of carbachol
(100%), or in the presence of lOpM-carbachol with
(-) or without (0) lOpM-GTPyS. The data show
the means + S.E.M. of data from six similar
experiments.
level of the plasma membrane by different guanine
nucleotide regulatory proteins, and (3) carried out
through the activation of different second messen-
ger systems. The data presented in the present
paper provide additional support for the hypoth-
esis that a guanine nucleotide binding protein
distinct from N, is involved in muscarinic choliner-
gic receptor action in 1321N I cells.
The involvement of a 'new' guanine nucleotide
regulatory protein in the cholinergic responses of
the 1321 NI cell initially was suggested by the
observation that pertussis toxin had no effect on
guanine-nucleotide-sensitive binding of carbachol
to muscarinic receptors. It is pertinent to note the
report of Boyer et al. (1984) who demonstrated that
guanine nucleotide-sensitive agonist binding to
renal a2-adrenergic receptors, but not acI-adrener-
gic receptors, was blocked by pertussis toxin
treatment. As is the case with one type of
muscarinic receptor, activation of a2-adrenergic
receptors has been shown to stimulate markedly
the breakdown of phosphoinositides (Fain &
Garcia-Sainz, 1980). The results presented here
demonstrate that, even though NEM directly
modifies the guanine nucleotide binding compo-
nent of Ni (Fig. 1) in 1321N1 cells, it has no effect
on the apparent affinity of carbachol in the
absence of guanine nucleotides or on the conver-
sion of the receptor to a lower affinity state by
GTPyS. Thus, these results support our previous
proposal that some component other than Ni must
be responsible for the guanine nucleotide modula-
tion of the affinity for muscarinic receptor agonists
in 1321N1 cells. If it is true that a muscarinic
receptor subtype exists that only couples to
adenylate cyclase while a second subtype couples
to phosphoinositide breakdown, then guanine
nucleotide-sensitive agonist binding to only the
former subtype would be sensitive to NEM. Thus,
regarding the current widely used terminology, it
could be proposed that agonist binding to M2- but
not M,-muscarinic receptors (Hammer et al.,
1980; Hammer & Giachetti, 1982) would be
sensitive to NEM.
Activation of muscarinic receptors of 1321 NI
cells results in phosphoinositide breakdown and
calcium mobilization (Masters et al., 1984). Fur-
thermore, cholinergic agonists display a distinctive
profile for stimulation of these responses in
1321 NI cells (Masters et al., 1984; Hepler et al.,
1984). Carbachol and methacholine are 'full'
agonists, while oxotremorine, bethanecol, areco-
line, and pilocarpine have 'partial' agonist proper-
ties. This pharmacological profile is similar to that
reported for muscarinic receptor-mediated stimu-
lation of phospholipid metabolism in chick heart
cells (Brown & Brown, 1984) and brain (Fisher et
al., 1983) and provides further evidence that a
specific receptor subtype mediates this response.
Furthermore, the binding of full agonists is
characterized by a large proportion of receptors in
a high affinity conformation and a large sensitivity
to modulation by guanine nucleotides (Hepler et
al., 1984). Guanine nucleotide-sensitive high-
affinity binding is less with partial agonists.
This correlation between agonist efficacy and the
capacity of agonists to form a guanine nucleotide-
sensitive high-affinity binding complex is another
factor that leads to consideration of a guanine
nucleotide regulatory protein as a candidate for
linking receptor stimulation to phosphoinositide
breakdown. It is significant in this regard that
pertussis toxin treatment does not affect muscar-
inic receptor-stimulated phosphoinositide break-
down or Ca2+ efflux in 1321N I cells (Masters et al.,
1985).
A number of recent reports have suggested that a
guanine nucleotide binding protein(s) may be
involved in receptor-mediated, Ca2+-induced pro-
cesses. Gomperts (1983) showed that the GTP
analogue guanosine 5'-[,By-imido]triphosphate in-
troduced into ATP4-permeabilized mast cells
enhanced histamine release in response to extracel-
lular Ca2 . In addition, Haslam & Davidson (1984)
suggested that GTP analogues had thrombin-like
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Several laboratories recently have presented evi-
dence that Ni or an N1-like protein is involved in
the sequelae of biochemical events that are closely
linked to the gating and influx of extracellular
calcium. Thus, pertussis toxin treatment sup-
pressed the Ca2+- or IgE-induced release of
histamine from mast cells (Nakamura & Ui, 1983;
Molski et al., 1984) and inhibited fMet-Leu-Phe-
stimulated superoxide anion formation, arachi-
donic acid release and influx of Ca2+ in neutrophils
(Nakamura & Ui, 1984; Okajima & Ui, 1984;
Bokoch & Gilman, 1984). These latter phenomena
can be distinguished from the muscarinic receptor-
stimulated events in 1321 NI cells since agonist
binding, phosphoinositide breakdown, mobiliza-
tion of intracellular calcium and activation of
cyclic nucleotide phosphodiesterase are insensitive
to pertussis toxin in the astrocytoma cell line.
Thus far, the evidence for existence in 1321 NI
cells of a functionally significant guanine nucleo-
tide regulatory protein distinct from those cur-
rently described is indirect. The recent discovery of
a new protein called Go from bovine brain
(Sternweis & Robishaw, 1984), and the discovery
that the product of the ras gene is a membrane-
bound guanine nucleotide binding protein (Shih et
al., 1980) show that this family of regulatory
proteins has room for new members. Interestingly,
the ras and other oncogene protein products have
been implicated in a number of steps in phosphoin-
ositide metabolism (Berridge & Irvine, 1984).
Whether any one of the newly described guanine
nucleotide regulatory proteins of unknown func-
tion is a necessary component of the muscarinic
receptor system of 1321 NI cells is yet to be proven.
T. K. H. is an Established Investigator of the
American Heart Association.
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